R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center.
Paolo Anderlini,Rima M. Saliba,Sandra Acholonu,Grace Julia Okoroji,Celina Ledesma,Borje S. Andersson,Roy B. Jones,Uday R. Popat,Chitra Hosing,Yago Nieto,Muzaffar H. Qazilbash,Naoto T. Ueno,Sergio Giralt,Marcos de Lima,Richard E. Champlin +14 more
TL;DR: It is felt that the designation “donor leukocyte infusion” is preferable to ‘donor lymphocytes infusion’, as clearly the infused product contains additional cell types in addition to lymphocytes, such as monocytes, natural killer (NK) cells, etc.
Journal ArticleDOI
Outcome after Frontline Therapy with the Hyper-CVAD and Imatinib Mesylate Regimen for Adults with De Novo or Minimally Treated Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
Deborah A. Thomas,Hagop M. Kantarjian,Jorge E. Cortes,Farhad Ravandi,Stefan Faderl,Dan Jones,Laurie Letvak,Partow Kebriaei,Richard E. Champlin,Susan O'Brien +9 more
TL;DR: The addition of imatinib improved outcome compared with hyper-CVAD alone (irrespective of allogeneic SCT); overall 3-yr CR duration and OS rates were 68% vs 25% and 55% vs 15%, respectively, p
Journal ArticleDOI
Poor immune reconstitution is associated with symptomatic BK polyomavirus viruria in allogeneic stem cell transplant recipients.
Ala Abudayyeh,Amir Hamdi,Maen Abdelrahim,Heather Lin,Valda D. Page,Gabriela Rondon,Borje S. Andersson,Aimaz Afrough,Charles Martinez,Jeffrey J. Tarrand,Dimitrios P. Kontoyiannis,David Marin,A. Osama Gaber,Betul Oran,Roy F. Chemaly,Sairah Ahmed,Islam Abudayyeh,Amanda Olson,Roy B. Jones,Uday R. Popat,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +22 more
TL;DR: Transplant‐associated variables and immune parameters that can predict for the risk of BKPyV viruria are determined and it is hypothesized that BK PyV infection is a marker of poor immune recovery.
Journal ArticleDOI
Primary Systemic Amyloid Light Chain Amyloidosis Decompensating After Filgrastim-Induced Mobilization and Stem-Cell Collection
Journal ArticleDOI
Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission
Betul Oran,Uday R. Popat,Gabriella Rondon,Farhad Ravandi,Guillermo Garcia-Manero,L. V. Abruzzo,Borje S. Andersson,Qaiser Bashir,Julianne Chen,Partow Kebriaei,Issa F. Khouri,Ebru Koca,Muzaffar H. Qazilbash,Richard E. Champlin,Marcos de Lima +14 more
TL;DR: The data suggest that patients with AML and unfavorable cytogenetics at diagnosis and a persistent abnormal clone at allo-HSCT are at high risk for relapse after allo -HSCT.